Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
2.150
+0.070 (3.37%)
At close: Mar 9, 2026, 4:00 PM EDT
2.190
+0.040 (1.86%)
After-hours: Mar 9, 2026, 4:11 PM EDT
Compugen Revenue
In the year 2025, Compugen had annual revenue of $72.76M with 161.14% growth. Compugen had revenue of $67.33M in the quarter ending December 31, 2025, with 4,477.29% growth.
Revenue (ttm)
$72.76M
Revenue Growth
+161.14%
P/S Ratio
2.69
Revenue / Employee
$983,297
Employees
74
Market Cap
203.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.76M | 44.90M | 161.14% |
| Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
| Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
| Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
| Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 154.90M |
| Arcturus Therapeutics Holdings | 82.03M |
| Editas Medicine | 46.38M |
| ProQR Therapeutics | 18.86M |
| Molecular Partners AG | 856.30K |
| NeOnc Technologies Holdings | 59.99K |
CGEN News
- 7 days ago - Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement - Seeking Alpha
- 7 days ago - Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Compugen Reports Fourth Quarter and Full Year 2025 Results - PRNewsWire
- 18 days ago - Compugen to Participate in Upcoming Investor Conferences - PRNewsWire
- 20 days ago - Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 - PRNewsWire
- 25 days ago - Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors - PRNewsWire
- 2 months ago - Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million - PRNewsWire
- 4 months ago - Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha